retatrutide phase 2 results 2024 2025 press release Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Weight Loss as Platform: Retatrutide

Acknowledgements This work was supported by American Cancer Society grant number DICRIDG-22103719901, National Science Foundation grant number 1912322, and National Institutes of Health grant R25AG070244 to Manoj Mishra

Semaglutide has proven heart health benefits, reducing risks of cardiovascular disease

Ozempic for PCOS may help manage some symptoms, particularly weight-related and metabolic issues linked to insulin resistance

A comprehensive metabolic panel that costs $500 in the United States might run $50 to $100 in Mexico

If youre interested in weight loss medications, talk with your healthcare provider about what options might work for you now, and keep retatrutide on your radar as it moves through the approval process